Provided by Tiger Trade Technology Pte. Ltd.

Veradermics, Inc.

102.82
-2.5000-2.37%
Post-market: 102.820.00000.00%19:30 EDT
Volume:393.62K
Turnover:41.10M
Market Cap:4.30B
PE:-15.96
High:108.87
Open:105.18
Low:102.52
Close:105.32
52wk High:131.24
52wk Low:32.00
Shares:41.78M
Float Shares:26.54M
Volume Ratio:0.64
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4439
EPS(LYR):-111.9114
ROE:-72.06%
ROA:-43.45%
PB:5.28
PE(LYR):-0.92

Loading ...

Company Profile

Company Name:
Veradermics, Inc.
Exchange:
NYSE
Establishment Date:
2019
Employees:
37
Office Location:
470 James Street,Suite 2,New Haven,Connecticut,United States
Zip Code:
06513
Fax:
- -
Introduction:
VeraDermics, Incorporated was founded on October 5, 2019, originally in Texas, and converted to a Delaware corporation on September 15, 2021. This late-stage clinical biopharmaceutical company, founded by dermatologists, focuses on developing innovative therapies for prevalent aesthetic and dermatological conditions. The company is primarily dedicated to addressing treatment challenges in patterned hair loss (PHL) and is advancing its lead candidate VDPHL01, an oral non-hormonal therapy designed to optimize hair growth while minimizing side effects associated with traditional treatments. VeraDermics is conducting pivotal clinical trials to support regulatory approval, aiming to transform the management of PHL through its targeted therapeutic approach.

Directors

Name
Position
Reid Waldman
Chief Executive Officer and Director
David Friedman
Independent Director
Jane Grant Kels
Independent Director
John W. Childs
Independent Director
Katarina Pance
Independent Director
Patrick Enright
Independent Director
Vlad Coric
Independent Director

Shareholders

Name
Position
Reid Waldman
Chief Executive Officer and Director
Dominic Carrano
Chief Financial Officer and Treasurer
Mark Neumann
Chief Commercial and Strategy Officer
Michael V. Greco
General Counsel
Tim Durso
Chief Technical Officer